Abstract
PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic immunity seems to be a prerequisite for efficacy, as recently shown in patients and in mouse models. It is widely accepted that expansion of anti-tumor CD8 T cell populations is principally responsible for anti-tumor responses. In contrast, the role of CD4 T cells has been less studied. Here we review and discuss the evidence supporting the contribution of CD4 T cells to anti-tumor immunity, especially recent advances linking CD4 T cell subsets to efficacious PD-L1/PD-1 blockade immunotherapy. We also discuss the role of CD4 T cell memory subsets present in peripheral blood before the start of immunotherapies, and their utility as predictors of response.
Funder
Spanish Association against Cancer
Instituto de Salud Carlos III (ISCIII)-FEDER
Department of Health of the Government of Navarre
Department of Industry, Government of Navarre
European Union’s Horizon 2020 research and innovation programme
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference191 articles.
1. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012
2. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N. Engl. J. Med.,2012
3. The foundations of immune checkpoint blockade and the ipilimumab approval decennial;Korman;Nat. Rev. Drug Discov.,2022
4. Chocarro, L., Arasanz, H., Fernandez-Rubio, L., Blanco, E., Echaide, M., Bocanegra, A., Teijeira, L., Garnica, M., Morilla, I., Martinez-Aguillo, M., CAR-T Cells for the Treatment of Lung Cancer. Life, 2022. 12.
5. Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy;Escors;New J. Sci.,2014
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献